MHRP last week launched a Phase 2 clinical trial in Thailand to evaluate an interleukin-15 (IL-15) superagonist, ImmunityBio’s Anktiva®, administered during acute HIV infection as an experimental therapy to target establishment of the HIV reservoir at a very early stage.
The National Agency for the Control of AIDS (NACA) in Nigeria launched new consolidated service delivery guidelines on HIV and sexually transmitted infections (STIs) for key populations in Nigeria.
